These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28972020)

  • 21. Getting to the Root of High Prescription Drug Prices.
    Waxman H; Corr B; Martin K; Duong S
    Issue Brief (Commonw Fund); 2017 Jul; 2017():1-10. PubMed ID: 28700190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Public research funding and pharmaceutical prices: do Americans pay twice for drugs?
    Conti RM; David FS
    F1000Res; 2020; 9():707. PubMed ID: 33204410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Economics of Indication-Based Drug Pricing.
    Chandra A; Garthwaite C
    N Engl J Med; 2017 Jul; 377(2):103-106. PubMed ID: 28700848
    [No Abstract]   [Full Text] [Related]  

  • 24. The Questionable Economic Case for Value-Based Drug Pricing in Market Health Systems.
    Pauly MV
    Value Health; 2017 Feb; 20(2):278-282. PubMed ID: 28237209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Value-Based Pricing and State Reform of Prescription Drug Costs.
    Hwang TJ; Kesselheim AS; Sarpatwari A
    JAMA; 2017 Aug; 318(7):609-610. PubMed ID: 28692713
    [No Abstract]   [Full Text] [Related]  

  • 26. Value-Based Pricing and Patient Access for Specialty Drugs.
    Robinson JC; Howell S; Pearson SD
    JAMA; 2018 Jun; 319(21):2169-2170. PubMed ID: 29801023
    [No Abstract]   [Full Text] [Related]  

  • 27. The challenge of paying for cost-effective cures.
    Zettler PJ; Fuse Brown EC
    Am J Manag Care; 2017 Jan; 23(1):62-64. PubMed ID: 28141931
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential pricing of new pharmaceuticals in lower income European countries.
    Kaló Z; Annemans L; Garrison LP
    Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting Unconscionable Prescription-Drug Prices - Maryland's Anti-Price-Gouging Law.
    Greene JA; Padula WV
    N Engl J Med; 2017 Jul; 377(2):101-103. PubMed ID: 28591520
    [No Abstract]   [Full Text] [Related]  

  • 30. Congress compromises on Medicaid drug pricing; 'best price' excludes VA, others.
    Am J Hosp Pharm; 1993 Jan; 50(1):16, 19. PubMed ID: 8427272
    [No Abstract]   [Full Text] [Related]  

  • 31. Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues.
    Danzon PM
    Pharmacoeconomics; 2018 Dec; 36(12):1395-1405. PubMed ID: 30062518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug pricing and value in oncology.
    Danzon PM; Taylor E
    Oncologist; 2010; 15 Suppl 1():24-31. PubMed ID: 20237214
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AMCP Guide to Pharmaceutical Payment Methods.
    AMCP Task Force on Drug Payment Methodologies
    J Manag Care Pharm; 2007 Oct; 13(8 Suppl C):S1-39. PubMed ID: 17970611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Value-Based Pricing for Drugs: Theme and Variations.
    Kaltenboeck A; Bach PB
    JAMA; 2018 Jun; 319(21):2165-2166. PubMed ID: 29710320
    [No Abstract]   [Full Text] [Related]  

  • 35. The pricing of pharmaceuticals: an international comparison.
    Dickson M
    Clin Ther; 1992; 14(4):604-10; discussion 603. PubMed ID: 1525794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation. Final rule; further delay of effective date.
    Health Resources and Services Administration, HHS
    Fed Regist; 2017 May; 82(96):22893-5. PubMed ID: 28574239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Managed Entry Agreements for Pharmaceutical Products in Middle East and North African Countries: Payer and Manufacturer Experience and Outlook.
    Maskineh C; Nasser SC
    Value Health Reg Issues; 2018 Sep; 16():33-38. PubMed ID: 29936067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multi-indication and Combination Pricing and Reimbursement of Pharmaceuticals: Opportunities for Improved Health Care through Faster Uptake of New Innovations.
    Persson U; Norlin JM
    Appl Health Econ Health Policy; 2018 Apr; 16(2):157-165. PubMed ID: 29470774
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Notice regarding Section 602 of the Veterans Health Care Act of 1992; new drug pricing--PHS. Final notice.
    Fed Regist; 1995 Oct; 60(190):51488-9. PubMed ID: 10151188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.